Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

AAPS PharmSci 360: CMC Strategies, Part 1

ByAlfred Rumondor, PhD,Swita Singh, PhD,Susan Haigney

September 2nd 2026

Novartis makes a $3.2 Billion bet on a subcutaneous formulation platform.

What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation

ByZachary Zubulake

September 2nd 2026

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 2

ByRobert Holt, PhD,Susan Haigney

September 2nd 2026

Medical award concept, winner cup on the desk | Image Credit: ©BillionPhotos.com -stock.adobe.com

CPHI Milan Names 2026 Pharma Awards Finalists

BySusan Haigney

September 1st 2026

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 1

ByRobert Holt, PhD

September 1st 2026

February 2003

Articles in this issue

Related Content

AAPS PharmSci 360: CMC Strategies, Part 1

What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 2

CPHI Milan Names 2026 Pharma Awards Finalists

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 1

Trending on Pharmaceutical Technology

What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation

AAPS PharmSci 360: CMC Strategies, Part 1

CPHI Milan Names 2026 Pharma Awards Finalists

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 1

From Phase 1 Screening to Commercial Strategy: Selecting the Right Amorphous Solid Dispersion Technology Early